The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Open accessAbstract
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS: We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS: A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post hoc and prespecified subgroup analyses and meta-analyses of 5 major fibrate trialsdHelsinki Heart Study, Veterans Affairs HDL Intervention Trial, Bezafibrate Infarction Project, FIELD, and ACCORD-Lipiddhave shown a CV benefit in persons with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL, either isolated or together) but not in persons without dyslipidemia.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits in outcome studies appear limited to subgroups with high TG and low HDL-C, highlighting the complexity of translating TG reduction into ASCVD risk reduction [61, 74–77].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, traditional TG-lowering agents, such as fibrates and niacin, have demonstrated inconsistent CVD benefits in randomized trials, even when lipid changes were robust.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the recently concluded AIM-HIGH study did not report any further benefits with regard to cardiovascular events when niacin was added to a statin in patients with median triglyceride level of about 160 mg/dl in the mild hypertriglyceridemia range and average LDL cholesterol levels below 80 mg/dl (177).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“whether lowering these levels would also lower the incidence of cardiovascular events remains controversial.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“These neutral findings with pemafibrate are consistent with those from the contemporary Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) trial 2 of high-dose n-3 fatty acids, the previous Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (160)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies, such as the Copenhagen City Heart Study involving 9330 individuals, indicate a progressive rise in myocardial infarction risk over a decade with increasing Lp(a) levels [13].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [30]
In the citing paper
“Combinations of statins with fibrates, niacin, or fish oil have thus far generally failed to demonstrate cardiovascular benefits beyond that achieved with statins alone.128–132”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [129]
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“In the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but did not reduce the risk of major CV events [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“Niacin also lowers LDL-C levels by 15–20%,49 but recent large randomized trials showed a significant excess of adverse effects and no significant CVD benefit when added to background statin treatment; therefore, niacin derivatives are no longer available for prescription in Europe.50,51”
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Twolarge randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Two large randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Modest regression of carotid atherosclerosis with niacin in most (but not all) imaging studies was not supported by clinical benefit in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Niacin did not reduce stroke over longterm follow-up in patients with CVD in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“With respect to primary endpoints of these studies, although the effectiveness of fenofibrate was not demonstrated, a meta-analysis in primary prevention using fibrates revealed that deaths from cerebrovascular and cardiovascular diseases, non-fatal myocardial infarction, and non-fatal stroke significantly decreased by 16%651).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [651]
In the citing paper
“Combination therapy using ethyl icosapentate (EPA) preparation or fibrate with statin is effective in suppressing ASCVD incidence. (Evidence level 2, recommendation level B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“In a sub-analysis of JELIS study696) which enrolled subjects with hypercholesterolemia, it was shown that EPA administration added-on to statins prevented coronary event incidence for patients in primary prevention whose TG and HDL-C levels were ≥ 151 mg/dL and < 40 mg/dL, respectively.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“Meta-analyses of studies with niacin (mostly without simultaneous administration of statins) indicate a decrease in cardiovascular events [92–94].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [92]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Flagged first, then by citations
Research works printed but not linked: 1
- Castelli WP, 1988, Can J Cardiol, 4, 5A
Cited by
Sorted by citations
Items 201–300 of 1,019
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
Otocka-Kmiecik, A., Mikhailidis, D. P., Nicholls, S. J., Davidson, M. H., Rysz, J., & Banach, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.03.003 · Cited by 207
Preiss, D., Lloyd, S. M., Ford, I., McMurray, J. J., Holman, R. R., Welsh, P., Fisher, M., Packard, C. J., & Sattar, N. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70152-9 · Cited by 187
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Madder, R. D., Goldstein, J. A., Madden, S., Puri, R., Wolski, K., Hendricks, M. J., Sum, S. T., Kini, A. S., Sharma, S., Rizik, D. G., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.04.012 · Cited by 205
Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease
de Gregorio, E., Colell, A., Morales, A., & Marı́, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113858 · Cited by 203
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 200
Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
Murphy, A. J., Bijl, N., Yvan‐Charvet, L., Welch, C. L., Bhagwat, N., Adili, R., Wang, Y., Shaw, J. A., Levine, R. L., Ni, H., et al. (2013) · Nature Medicine · doi:10.1038/nm.3150 · Cited by 201
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerlekar, N., Nicholls, S. J., & Layland, J. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 209
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196
Optimizing cholesterol treatment in patients with muscle complaints
Rosenson, R. S., Baker, S., Banach, M., Borow, K. M., Braun, L. T., Bruckert, E., Brunham, L. R., Catapano, A. L., Elam, M. B., Mancini, G. B. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.752 · Cited by 193
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL function
Millar, C. L., Duclos, Q., & Blesso, C. N. (2017) · Advances in Nutrition · doi:10.3945/an.116.014050 · Cited by 208
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, B. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 194
Contribution of remnant cholesterol to cardiovascular risk
Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13059 · Cited by 194
Gibson, C. M., Korjian, S., Tricoci, P., Daaboul, Y., Yee, M., Jain, P., Alexander, J. H., Steg, P. G., Lincoff, A. M., Kastelein, J. J. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025687 · Cited by 193
Stroke Prevention - Medical and Lifestyle Measures
Sarıkaya, H., Ferro, J. M., & Arnold, M. (2015) · European Neurology · doi:10.1159/000367652 · Cited by 201
Dyslipidemia in patients with chronic kidney disease
Hager, M., Narla, A. D., & Tannock, L. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9402-z · Cited by 195
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Effects of curcumin on HDL functionality
Ganjali, S., Blesso, C. N., Banach, M., Pirro, M., Majeed, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.008 · Cited by 186
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0159-y · Cited by 193
Nicholls, S. J., Andrews, J., Kastelein, J. J. P., Merkely, B. P., Nissen, S. E., Ray, K. K., Schwartz, G. G., Worthley, S. G., Keyserling, C., Dasseux, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2121 · Cited by 191
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Tardif, J., Rhéaume, É., Perreault, L. L., Grégoire, J. C., Zada, Y. F., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L’Allier, P. L., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000663 · Cited by 183
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 188
Annema, W., & von Eckardstein, A. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1025 · Cited by 185
Postprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 183
Cheeley, M. K., Saseen, J. J., Agarwala, A., Ravilla, S., Ciffone, N., Jacobson, T. A., Dixon, D. L., & Maki, K. C. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.05.068 · Cited by 197
Desai, N. R., Kohli, P., Giugliano, R. P., O’Donoghue, M. L., Somaratne, R. M., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001969 · Cited by 179
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations
Noels, H., Lehrke, M., Vanholder, R. C., & Jankowski, J. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00423-5 · Cited by 183
I Diretriz Brasileira de Prevenção Cardiovascular
Simão, A., Précoma, D., Andrade, J., Filho, H. C., Saraiva, J., Oliveira, G., Murro, A., Campos, A., Alessi, A., Avezum, Á., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s012 · Cited by 186
Intolerance to Statins: Mechanisms and Management
Bitzur, R., Cohen, H., Kamari, Y., & Harats, D. (2013) · Diabetes Care · doi:10.2337/dcs13-2038 · Cited by 185
Relationship of Lipoproteins to Cardiovascular Events
Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.023 · Cited by 182
Hydroxy-Carboxylic Acid Receptor Actions in Metabolism
Offermanns, S. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.007 · Cited by 186
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Hoover-Plow, J. L., & Huang, M. (2012) · Metabolism · doi:10.1016/j.metabol.2012.07.024 · Cited by 175
Nicholls, S. J., Puri, R., Ballantyne, C. M., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Wright, R. S., Kallend, D. G., Wijngaard, P. L. J., Borgman, M., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2112 · Cited by 178
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Free Fatty Acid (FFA) and Hydroxy Carboxylic Acid (HCA) Receptors
Offermanns, S. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135945 · Cited by 178
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
High-Density Lipoprotein Cholesterol and Mortality
Hamer, M., O’Donovan, G., & Stamatakis, E. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
High-Density Lipoprotein and Atherosclerosis Regression
Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.300760 · Cited by 172
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 172
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166
Stringhini, S., Tabák, Á. G., Akbaraly, T. N., Sabia, S., Shipley, M. J., Marmot, M. G., Brunner, E. J., Batty, G. D., Bovet, P., & Mika Kivimaki, B. (2012) · BMJ · doi:10.1136/bmj.e5452 · Cited by 163
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 170
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Cook, D. A., & West, C. P. (2012) · Academic Medicine · doi:10.1097/acm.0b013e31827c3d78 · Cited by 161
Arvanitis, M., & Lowenstein, C. J. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202306200 · Cited by 174
2017 Taiwan lipid guidelines for high risk patients
Li, Y., Ueng, K., Jeng, J., Charng, M., Lin, T., Chien, K., Wang, C., Chao, T., Liu, P., Su, C., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 166
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 168
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
Chen, S.-C., & Tseng, C. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.88 · Cited by 158
The role of lipoprotein (a) in chronic kidney disease
Hopewell, J. C., Haynes, R., & Baigent, C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083626 · Cited by 164
Hirata, A., Sugiyama, D., Watanabe, M., Tamakoshi, A., Iso, H., Kotani, K., Kiyama, M., Yamada, M., Ishikawa, S., Murakami, Y., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.014 · Cited by 150
High-Density Lipoprotein Function and Dysfunction in Health and Disease
Chiesa, S. T., & Charakida, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06846-w · Cited by 155
Fotakis, P., Kothari, V. M., Thomas, D. G., Westerterp, M., Molusky, M. M., Altin, E. S., Abramowicz, S., Wang, N., He, Y., Heinecke, J. W., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313253 · Cited by 156
Zhang, T., Chen, J., Tang, X., Luo, Q., Xu, D., & Yu, B. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1170-9 · Cited by 163
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 149
Systemic and renal lipids in kidney disease development and progression
WAHL, P. W., Ducasa, G. M., & Fornoni, A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00375.2015 · Cited by 147
Sahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 148
Verbeek, R., Hoogeveen, R. M., Langsted, A., Stiekema, L. C. A., Verweij, S. L., Hovingh, G. K., Wareham, N. J., Khaw, K., Boekholdt, S. M., Nordestgaard, B. G., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy334 · Cited by 147
Mechanisms and Treatment of Dyslipidemia in Diabetes
Bahiru, E. M., Hsiao, R., Philipson, D. J., & Watson, K. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01455-w · Cited by 145
Sattar, N. A., Preiss, D., Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R. M., Wasserman, S. M., & Raal, F. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00003-6 · Cited by 143
The impact of aerobic exercise on HDL quantity and quality: a narrative review
Franczyk, B., Gluba-Brzózka, A., Ciałkowska-Rysz, A., Ławiński, J., & Rysz, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054653 · Cited by 142
Genetics of Coronary Artery Disease
Roberts, R. (2014) · Circulation Research · doi:10.1161/circresaha.114.302692 · Cited by 144
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
High-density lipoprotein subclasses and their relationship to cardiovascular disease
Superko, H. R., PENDYALA, L. K., Williams, P. T., Momary, K. M., King, S. B., & Garrett, B. C. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.03.001 · Cited by 142
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 142
Natural approaches in metabolic syndrome management
Patti, A. M., Al‐Rasadi, K., Giglio, R. V., Nikolić, D., Mannina, C. M., Castellino, G., Chianetta, R., Banach, M., Cicero, A. F. G., Lippi, G., et al. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.68717 · Cited by 141
High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential
Jomard, A., & Osto, E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00039 · Cited by 154
Zhong, G., Huang, S.-Q., Peng, Y., Wan, L., Wu, Y., Hu, T., Hu, J., & Hao, F. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320914756 · Cited by 141
Averna, M. R., Banach, M., Bruckert, É., Drexel, H., Farnier, M., Gaiță, D. I., Magni, P., März, W., Masana, L., Silva, A. M. E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 143
Berberich, A. J., & Hegele, R. A. (2013) · Nutrients · doi:10.3390/nu5030981 · Cited by 143
Siam, N. H., Snigdha, N. N., Tabasumma, N., & Parvin, I. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512436 · Cited by 171
Modulation of adiponectin as a potential therapeutic strategy
Lim, S. K., Quon, M. J., & Koh, K. K. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.051 · Cited by 140
Nitric Oxide: Considerations for the Treatment of Ischemic Stroke
Terpolilli, N. A., Moskowitz, M. A., & Plesnila, N. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.12 · Cited by 139
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 137
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.279463 · Cited by 133
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
Casula, M., Colpani, O., Xie, S., Catapano, A. L., & Baragetti, A. (2021) · Cells · doi:10.3390/cells10081869 · Cited by 149
Reiss, A. B., Voloshyna, I., Leon, J. D., Miyawaki, N., & Mattana, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.028 · Cited by 135
Kirkland, J. B., & Meyer‐Ficca, M. L. (2018) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2017.11.003 · Cited by 141
van der Made, S. M., Plat, J., & Mensink, R. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118393 · Cited by 131
Otis, J. P., Zeituni, E. M., Thierer, J. H., Anderson, J. L., Brown, A., Boehm, E. D., Cerchione, D. M., Ceasrine, A. M., Avraham‐Davidi, I., Tempelhof, H., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.018754 · Cited by 131
Lipoprotein apheresis to treat elevated lipoprotein (a)
Waldmann, E., & Parhofer, K. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r056549 · Cited by 131
Thacker, S. G., Zarzour, A., Chen, Y., Alçiçek, M. S., Freeman, L. A., Sviridov, D. O., Demosky, S. J., & Remaley, A. T. (2016) · Immunology · doi:10.1111/imm.12638 · Cited by 135
Trends in lipid-modifying agent use in 83 countries
Blais, J. E., Wei, Y., Yap, K. K. W., Alwafi, H. H., Ma, T., Brauer, R., Lau, W. C. Y., Man, K. K. C., Siu, C. W., Tan, K. C. B., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.016 · Cited by 131
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01075-x · Cited by 156
Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Metadata
- Authors
- The AIM-HIGH Investigators
- Corresponding author
- The AIM-HIGH Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-15
- Volume
- 365
- Issue
- 24
- Pages
- 2255-2267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2165605025
- Semantic Scholar
- d76ac03611110eeffa5c3ad8b47d06f372d84eb6
- Cited by
- 2,911
- References
- 19
- Citations by year
- 2026: 79 · 2025: 90 · 2024: 138 · 2023: 133 · 2022: 138 · 2021: 165 · 2020: 146 · 2019: 181 · 2018: 208 · 2017: 203 · 2016: 264 · 2015: 302 · 2014: 316 · 2013: 333 · 2012: 192
- FWCI
- 280.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- Sanofi
- Genentech
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nicotinic acid, simvastatin, HDL cholesterol, low HDL cholesterol, residual cardiovascular risk, atherosclerotic cardiovascular disease, extended-release niacin, ezetimibe, LDL cholesterol, triglycerides, major adverse cardiovascular events, cardiovascular risk reduction, statin therapy, coronary artery disease, myocardial infarction, ischemic stroke, acute coronary syndrome, revascularization
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Brain Ischemia, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Muscular Diseases, Niacin, Triglycerides, Proportional Hazards Models, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Atherosclerosis, Kaplan-Meier Estimate, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
